Abeona Therapeutics (ABEO) Expected to Announce Quarterly Earnings on Thursday

Abeona Therapeutics (NASDAQ:ABEO) will likely be releasing its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect the company to post earnings of ($0.23) per share and revenue of $12.2380 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 13, 2026 at 8:30 AM ET.

Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings data on Wednesday, May 13th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.03. The firm had revenue of $8.72 million for the quarter, compared to analyst estimates of $4.57 million. On average, analysts expect Abeona Therapeutics to post $-1 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Abeona Therapeutics Price Performance

Shares of ABEO opened at $7.45 on Tuesday. The firm has a market cap of $424.58 million, a PE ratio of 7.68 and a beta of 1.35. Abeona Therapeutics has a 52-week low of $4.00 and a 52-week high of $7.54. The business’s 50 day moving average price is $6.22 and its two-hundred day moving average price is $5.53. The company has a debt-to-equity ratio of 0.03, a quick ratio of 5.70 and a current ratio of 5.89.

Insider Buying and Selling

In other Abeona Therapeutics news, insider Madhav Vasanthavada sold 12,606 shares of Abeona Therapeutics stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $6.96, for a total value of $87,737.76. Following the transaction, the insider directly owned 290,623 shares of the company’s stock, valued at $2,022,736.08. The trade was a 4.16% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Eric Crombez sold 26,143 shares of the firm’s stock in a transaction on Friday, May 15th. The stock was sold at an average price of $5.53, for a total value of $144,570.79. Following the completion of the sale, the director directly owned 37,313 shares of the company’s stock, valued at $206,340.89. The trade was a 41.20% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 307,221 shares of company stock worth $1,854,494 over the last 90 days. Insiders own 7.10% of the company’s stock.

Institutional Investors Weigh In On Abeona Therapeutics

Large investors have recently modified their holdings of the stock. XTX Topco Ltd raised its position in shares of Abeona Therapeutics by 25.4% in the 4th quarter. XTX Topco Ltd now owns 49,338 shares of the biopharmaceutical company’s stock worth $260,000 after acquiring an additional 9,979 shares in the last quarter. Tang Capital Management LLC bought a new stake in shares of Abeona Therapeutics during the fourth quarter valued at approximately $5,270,000. Balyasny Asset Management L.P. purchased a new stake in Abeona Therapeutics in the fourth quarter worth $3,118,000. J. Goldman & Co LP bought a new position in Abeona Therapeutics in the fourth quarter worth $2,102,000. Finally, AQR Capital Management LLC increased its stake in shares of Abeona Therapeutics by 240.7% in the 4th quarter. AQR Capital Management LLC now owns 114,520 shares of the biopharmaceutical company’s stock worth $604,000 after acquiring an additional 80,908 shares in the last quarter. Institutional investors own 80.56% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently issued reports on ABEO. HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of Abeona Therapeutics in a research report on Thursday, May 28th. Weiss Ratings lowered Abeona Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, August 3rd. Finally, Wall Street Zen raised Abeona Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 1st. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Abeona Therapeutics currently has an average rating of “Hold” and a consensus target price of $19.00.

Abeona Therapeutics Company Profile

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.